(Q51452446)

5 April 2018

title

Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. (English)

1 reference

5 April 2018

1 reference

Kharasch ED

1

1 reference

5 April 2018

Jubert C

2

1 reference

5 April 2018

Senn T

3

1 reference

5 April 2018

Bowdle TA

4

1 reference

5 April 2018

Thummel KE

5

1 reference

5 April 2018

publication date

1 July 1999

1 reference

5 April 2018

The Journal of Clinical Pharmacology

published in

1 reference

5 April 2018

volume

39

1 reference

5 April 2018

issue

7

1 reference

5 April 2018

page(s)

664-669

1 reference

5 April 2018

The human drug metabolizing cytochromes P450.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Substrates of human hepatic cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Gender effects in pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

First-pass metabolism of midazolam by the human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Physiologic and temporal variation in hepatic elimination of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Influence of food on midazolam absorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Exercise alters the pharmacokinetics of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Dose dependent pharmacokinetics of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Influence of age on the pharmacokinetics of alfentanil. Gender dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

No evidence of a genetic polymorphism in the oxidative metabolism of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine*

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Noninvasive tests of CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

First-pass metabolism of cyclosporin by the gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008290

10.1177/00912709922008290

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

release_5xaoernakfbctlvhxlqrv3nawe

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5xaoernakfbctlvhxlqrv3nawe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

5 April 2018